Lipid nanoparticle-based mRNA delivery systems for cancer immunotherapy

  • Nano Converg. 2023 Aug 7;10(1):36. doi: 10.1186/s40580-023-00385-3.
Jieun Han  #  1  2 ,  Jaesung Lim  #  3  4 ,  Chi-Pin James Wang  3  4 ,  Jun-Hyeok Han  1  4 ,  Ha Eun Shin  1 ,  Se-Na Kim  5 ,  Dooyong Jeong  6 ,  Sang Hwi Lee  6 ,  Bok-Hwan Chun  6 ,  Chun Gwon Park  7  8  9 ,  Wooram Park  10  11
Affiliations
  • 1. Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University, Seobu-ro 2066, Suwon, Gyeonggi, 16419, Republic of Korea.
  • 2. Institute of Biotechnology and Bioengineering, College of Biotechnology and Bioengineering, Sungkyunkwan University, Seobu-ro 2066, Suwon, Gyeonggi, 16419, Republic of Korea.
  • 3. Department of Biomedical Engineering, SKKU Institute for Convergence, Sungkyunkwan University (SKKU), Seobu-ro 2066, Suwon, Gyeonggi, 16419, Republic of Korea.
  • 4. Department of Intelligent Precision Healthcare Convergence, SKKU Institute for Convergence, Sungkyunkwan University, Seobu-ro 2066, Suwon, Gyeonggi, 16419, Republic of Korea.
  • 5. MediArk, Chungdae-ro 1, Seowon-gu, Cheongju, Chungcheongbuk, 28644, Republic of Korea.
  • 6. R&D center of HLB Pharmaceutical Co., Ltd., Hwaseong, Gyeonggi, 18469, Republic of Korea.
  • 7. Department of Biomedical Engineering, SKKU Institute for Convergence, Sungkyunkwan University (SKKU), Seobu-ro 2066, Suwon, Gyeonggi, 16419, Republic of Korea. [email protected].
  • 8. Department of Intelligent Precision Healthcare Convergence, SKKU Institute for Convergence, Sungkyunkwan University, Seobu-ro 2066, Suwon, Gyeonggi, 16419, Republic of Korea. [email protected].
  • 9. Biomedical Institute for Convergence at SKKU (BICS), Sungkyunkwan University, Seobu-ro 2066, Suwon, Gyeonggi, 16419, Republic of Korea. [email protected].
  • 10. Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University, Seobu-ro 2066, Suwon, Gyeonggi, 16419, Republic of Korea. [email protected].
  • 11. Institute of Biotechnology and Bioengineering, College of Biotechnology and Bioengineering, Sungkyunkwan University, Seobu-ro 2066, Suwon, Gyeonggi, 16419, Republic of Korea. [email protected].
  • # Contributed equally.
PMID: 37550567 DOI: 10.1186/s40580-023-00385-3
Abstract

Cancer Immunotherapy, which harnesses the power of the immune system, has shown immense promise in the fight against malignancies. Messenger RNA (mRNA) stands as a versatile instrument in this context, with its capacity to encode tumor-associated Antigens (TAAs), immune cell receptors, cytokines, and antibodies. Nevertheless, the inherent structural instability of mRNA requires the development of effective delivery systems. Lipid Nanoparticles (LNPs) have emerged as significant candidates for mRNA delivery in Cancer Immunotherapy, providing both protection to the mRNA and enhanced intracellular delivery efficiency. In this review, we offer a comprehensive summary of the recent advancements in LNP-based mRNA delivery systems, with a focus on strategies for optimizing the design and delivery of mRNA-encoded therapeutics in Cancer treatment. Furthermore, we delve into the challenges encountered in this field and contemplate future perspectives, aiming to improve the safety and efficacy of LNP-based mRNA Cancer immunotherapies.

Keywords
Cancer immunotherapy; Lipid nanoparticles (LNPs); Messenger RNA (mRNA); Tumor-associated antigens (TAAs).
Products